Review Article

Hepatology International

, Volume 7, Supplement 2, pp 833-841

First online:

Pharmacological agents for nonalcoholic steatohepatitis

  • Maeva GuillaumeAffiliated withService d’Hépatologie et Gastro-entérologie, INSERM 1048 and Université Paul Sabatier, Hôpital Purpan, Centre Hospitalier Universitaire de ToulouseService d’Hépatologie et Gastro-entérologie, Hôpital Purpan
  • , Vlad RatziuAffiliated withINSERM U938, Hospital Pitié Salpêtrière, CdR Saint-Antoine and Université Pierre et Marie CurieService d’Hépatologie et Gastro-entérologie, Hôpital Pitié-Salpêtrière Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The rationale for specific pharmacologic therapy in nonalcoholic steatohepatitis (NASH) is determined by the potential for disease progression and the difficulties, in many patients, to successfully implement diet and lifestyle changes in the long term. Because they correct insulin resistance, insulin-sensitizing agents are attractive candidates for the treatment of NASH. However, two randomized studies have shown that vitamin E, despite having no effect on insulin sensitivity, achieves interesting histological and biochemical efficacy. This review provides an insight into the therapeutic efficacy and safety issues of different pharmacological agents tested in human NASH.


Steatohepatitis Fibrosis Steatosis Glitazones Vitamin E Ursodesoxycholic acid Insulin resistance Oxidative stress Insulin sensitizers